Assenagon Asset Management S.A. Decreases Stock Position in Glaukos Co. (NYSE:GKOS)

Assenagon Asset Management S.A. trimmed its position in shares of Glaukos Co. (NYSE:GKOS) by 24.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,984 shares of the medical instruments supplier’s stock after selling 18,814 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.10% of Glaukos worth $8,544,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new position in Glaukos in the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd increased its holdings in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the last quarter. KBC Group NV lifted its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares in the last quarter. Brighton Jones LLC acquired a new position in Glaukos during the second quarter worth $208,000. Finally, EWA LLC purchased a new stake in Glaukos in the 3rd quarter valued at $209,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,603 shares of company stock worth $2,605,678 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on GKOS. BTIG Research lifted their price target on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. UBS Group initiated coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company. Wells Fargo & Company raised their target price on shares of Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Stifel Nicolaus increased their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Finally, JPMorgan Chase & Co. upped their target price on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.75.

Glaukos Trading Up 0.1 %

NYSE:GKOS opened at $156.60 on Monday. Glaukos Co. has a 52-week low of $83.90 and a 52-week high of $161.13. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $145.94 and a 200-day simple moving average of $133.60. The company has a market capitalization of $8.63 billion, a PE ratio of -51.85 and a beta of 1.04.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s revenue was up 23.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.50) EPS. On average, equities research analysts expect that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.